September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE

Muhammad Ibrahim/LinkedIn

Jan 25, 2026, 15:25

Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE

Muhammad Ibrahim, Medical Researcher at Research Council of Pakistan, shared on LinkedIn:

”Excited to co-author this amazing systematic review and meta-analysis entitled: Efficacy and Safety of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism.

Clinical question: Should we continue DOACs long-term after initial VTE treatment?

Analysis of 5,600+ patients from RCTs showed:

83% reduction in VTE recurrence
62% reduction in all-cause mortality
No significant increase in major bleeding
Higher clinically relevant non-major bleeding

Bottom line: In properly selected, low-bleeding-risk patients, extended DOAC therapy provides a clear net clinical benefit for secondary prevention of VTE.

Special thanks to Saad Ahmed Waqas for giving me the opportunity to work on and help lead this project.

Read here.

Congratulations to the co-authors: Muhammad Waqas, Muhammad Ahmed, Maimoona Nasir, Muhammad Khalid Afridi, Gregg C. Fonarow.”

Article: Efficacy and Safety of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors: Waqas Muhammad, Muhammad Ahmed, Muhammad Ibrahim, Maimoona Nasir, Muhammad Khalid Afridi, Gregg C. Fonarow, Saad Ahmed Waqas

Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE